Preimplantation Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Procedure (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), By Product (Reagents and Consumables, Instruments, Software), By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), Others), By Application (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, Other), By End User (Fertility Centers, Hospitals, Diagnostic Centers, Research Centers and Academic Labs), By Region & Competition, 2020-2030F

Market Overview

Global Preimplantation Genetic Testing market was valued at USD 655.30 Million in 2024 and is expected to reach USD 1053.87 Million by 2030 with a CAGR of 8.20%. Preimplantation Genetic Testing is a medical procedure used in assisted reproductive technology (ART) to screen embryos for genetic abnormalities before they are implanted into the uterus. It is primarily employed during in vitro fertilization (IVF) treatments to increase the chances of a successful pregnancy and reduce the risk of passing on certain genetic disorders to the child. There are two main types of preimplantation genetic testing: PGT-A (Preimplantation Genetic Testing for Aneuploidy): This type of testing is used to screen embryos for numerical chromosomal abnormalities, specifically aneuploidies.

Aneuploidy is a condition where there is an abnormal number of chromosomes in an embryo, which can lead to miscarriages or birth defects such as Down syndrome. PGT-A helps identify embryos with the correct number of chromosomes, increasing the likelihood of a successful pregnancy. PGT-M (Preimplantation Genetic Testing for Monogenic Disorders): PGT-M is used to detect specific genetic mutations or disorders that are known to run in a family. It is employed when one or both parents carry a known genetic mutation that could lead to serious health conditions in their offspring, such as cystic fibrosis or Huntington's disease. PGT-M allows the selection of embryos that do not carry the genetic mutation.

Key Market Drivers

Rising Incidence of Genetic Disorders

The rising incidence of genetic disorders is a significant driver for the growth of the global Preimplantation Genetic Testing (PGT) market. Globally, genetic disorders impact an estimated 2% to 5% of all live births. When tracked through early adulthood (up to age 25), approximately 5.3% of individuals are diagnosed with a genetic condition. These disorders span across chromosomal abnormalities, single-gene mutations, and complex multi-factorial diseases.

This prevalence underscores a significant and sustained burden on healthcare systems, presenting a growing market opportunity for advanced diagnostics, early intervention solutions, and long-term genetic disorder management strategies. There is a rising demand for preimplantation genetic testing (PGT) among couples with a known family history of genetic disorders or identified as carriers of specific mutations, driven by the need to mitigate transmission risks to future offspring. This demand is particularly pronounced in regions like the Middle East and North Africa, where consanguineous marriages constitute 20% to 50% of all unions. The elevated genetic risk profile in these populations is fueling the uptake of PGT services, positioning the region as a high-growth market for specialized reproductive genetics solutions. PGT offers them a way to identify embryos unaffected by these disorders before implantation, thereby increasing the chances of having a healthy child. PGT allows for comprehensive genetic screening of embryos at an early stage of development.

This technology can detect a wide range of genetic abnormalities, including single gene disorders and chromosomal aneuploidies. As the accuracy and sensitivity of genetic screening techniques improve, more couples are inclined to undergo PGT to ensure the genetic health of their embryos. There is a clear global shift in maternal age demographics, with a growing number of women deferring childbirth to their 30s and 40s, driven by career priorities, financial planning, and access to advanced reproductive technologies. Delayed childbearing, often associated with advanced maternal age, is linked to an increased risk of genetic abnormalities in offspring. As women postpone pregnancies, the likelihood of chromosomal abnormalities such as Down syndrome rises. PGT provides a solution for assessing embryos and selecting those with a lower risk of such abnormalities, addressing the age-related risks associated with delayed childbearing. The growing awareness about genetic disorders and the availability of advanced medical technologies have made more individuals and couples proactive in seeking solutions to mitigate these risks. As awareness spreads, more people are considering PGT as a viable option, contributing to the market's growth.

Advancements in Genetic Screening Technologies

Advancements in genetic screening technologies play a crucial role in driving the growth of the global Preimplantation Genetic Testing (PGT) market. These technological innovations enhance the accuracy, efficiency, and accessibility of PGT procedures, making them more appealing and feasible for a wider range of individuals and couples. Advanced genetic screening technologies offer higher accuracy and reliability in detecting genetic abnormalities and mutations in embryos. This increased precision reduces false-positive and false-negative results, leading to more informed decision-making during the embryo selection process. 

Newer technologies enable comprehensive genetic analysis of embryos, allowing for the simultaneous screening of multiple genetic disorders and chromosomal abnormalities. This expanded scope of analysis provides a more comprehensive assessment of the genetic health of embryos, attracting couples seeking a thorough evaluation. Advancements in genetic screening often lead to the development of non-invasive or minimally invasive techniques for embryo assessment. This reduces the need for extensive sample collection from embryos, making the procedure less stressful and potentially safer for both the embryo and the mother. 

Technologies that allow the analysis of a single cell from an embryo (single-cell analysis) enable accurate detection of genetic mutations, even in cases where only a small number of cells are available. This is particularly useful for embryos at an early developmental stage, enhancing the potential pool of embryos eligible for testing. Automation and high-throughput screening technologies streamline the PGT process, allowing clinics to handle larger volumes of samples efficiently. This scalability contributes to the growth of the PGT market by accommodating a higher number of patients.

Rising demand for IVF

The rising demand for in vitro fertilization (IVF) procedures significantly drives the growth of the global Preimplantation Genetic Testing (PGT) market. According to a recent WHO report, approximately 17.5% of the global adult population equivalent to 1 in 6 individuals faces infertility. This high prevalence highlights a critical gap in accessible, affordable, and quality fertility care. The data underscores a growing, unmet demand across both developed and emerging markets, signaling strategic opportunities for providers of advanced fertility solutions and healthcare systems aiming to expand equitable reproductive care services. IVF and PGT are often integrated to enhance the success rates of fertility treatments and ensure healthier pregnancies. 

PGT is commonly used alongside IVF to assess the genetic health of embryos before implantation. As the demand for IVF increases, more individuals and couples are exposed to the option of combining IVF with PGT, leading to higher adoption rates of PGT services. The combination of IVF with PGT allows healthcare providers to select embryos with a lower risk of genetic abnormalities for implantation. This increases the likelihood of successful pregnancies and live births, which is a major factor driving couples to opt for PGT as part of their IVF treatment. Advanced maternal age is associated with a higher risk of genetic disorders and chromosomal abnormalities in offspring. As more women delay childbearing, the demand for IVF and PGT services increases to address the age-related risks, contributing to the growth of the PGT market. Some couples may require multiple IVF cycles to achieve a successful pregnancy.

PGT helps optimize the selection of embryos for transfer, potentially reducing the number of cycles needed and the associated physical, emotional, and financial burdens. Factors such as lifestyle changes, environmental influences, and medical conditions contribute to fertility challenges for many couples. As infertility becomes more prevalent worldwide, the demand for fertility treatments like IVF, often combined with PGT, continues to rise. Growing awareness about fertility treatment options, including IVF and PGT, encourages more individuals and couples to explore these technologies to fulfill their desire for parenthood. 

The availability of advanced IVF and PGT technologies in certain countries has led to medical tourism, where individuals and couples travel to access these services. This trend further boosts the demand for PGT as part of IVF treatment. Ongoing advancements in IVF techniques and protocols contribute to higher success rates, making IVF a more attractive option for couples struggling with infertility. PGT complements these advancements by offering genetic screening to improve pregnancy outcomes.

Download Free Sample Report

Key Market Challenges

Ethical And Moral Concern

The use of PGT to select for certain traits, such as eye color or intelligence, could lead to discrimination against people who do not have those traits. This is because PGT could make it more likely that people with certain traits will be born, and less likely that people with other traits will be born. This could lead to a society where people are divided into different groups based on their genetic makeup. The use of PGT to screen for genetic diseases could lead to the abortion of embryos that have these diseases. This is a controversial issue, as some people believe that abortion is morally wrong. Others believe that it is justified in cases where the embryo has a serious genetic disease. The use of PGT could lead to the creation of a "designer baby". This is a hypothetical scenario in which parents use PGT to select for certain traits in their child, such as intelligence, athletic ability, or beauty. This could lead to a society where people are judged based on their genetic makeup, rather than their individual merits.

Inaccuracies and False Positives/Negatives

Inaccuracies can lead to the selection of embryos that are not free of genetic diseases. This could result in the birth of a child with a genetic disease. False positives can lead to the discarding of embryos that are healthy. This could reduce the chances of a successful pregnancy. False negatives can lead to the implantation of embryos that have genetic diseases. This could result in the birth of a child with a genetic disease.

Limited Access and Awareness

PGT is a relatively new technology, and it is not yet available in all countries. Even in countries where it is available, it may not be offered by all IVF clinics. This can make it difficult for people to access PGT, especially those who live in rural areas or who have limited financial resources. Many people are not aware of PGT or its benefits. This can make it difficult for people to make informed decisions about whether or not to use the procedure. These challenges can limit the growth of the PGT market. In order to address these challenges, it is important to increase access to PGT and to raise awareness about the procedure. This can be done by educating healthcare providers, patients, and the general public about PGT. It is also important to make PGT more affordable, so that it is accessible to more people.

Key Market Trends

Growing Number of Fertility Clinics Offering Preimplantation Genetic Testing (PGT) Services

The global Preimplantation Genetic Testing market, As more fertility clinics offer PGT services, the accessibility of these services to a larger population of prospective parents increases. This trend helps to bring PGT procedures closer to those seeking reproductive assistance, making it easier for individuals or couples to access genetic testing and make informed decisions about their family planning. The expansion of PGT services to more fertility clinics means that people in a wider range of geographic locations can benefit from genetic testing. This is particularly important for individuals who may not have easy access to specialized medical centers or major metropolitan areas. Fertility clinics that offer PGT often provide a comprehensive suite of reproductive services, including in vitro fertilization (IVF) and related procedures. This integrated approach allows patients to receive a full range of fertility and genetic services under one roof. The growth of fertility clinics offering PGT services leads to increased competition within the market. Competition can drive improvements in service quality, technological offerings, and pricing, ultimately benefiting patients by providing more options and potentially lowering costs. The expansion of PGT services to more fertility clinics indicates a wider adoption of advanced genetic testing technologies within the reproductive medicine field. This trend may encourage further innovation and investment in genetic testing techniques, leading to improved accuracy, faster results, and the ability to test for a broader range of genetic conditions.

Segmental Insights

Procedure Insights

Based on the category of Procedure, the Preimplantation Genetic Diagnosis (PGD) segment emerged as the fastest growing in the market for Preimplantation Genetic Testing in 2024. PGD is specifically used to detect inherited single-gene disorders and chromosomal abnormalities in embryos before implantation, making it highly relevant for couples with a known family history of genetic diseases or those identified as carriers through genetic screening. Unlike PGT-A, which focuses on chromosomal count, PGD offers a precision-based solution to avoid transmission of specific genetic conditions such as cystic fibrosis, thalassemia, Huntington’s disease, and BRCA mutations. This targeted application drives demand, particularly among high-risk populations.

The increasing uptake of carrier screening panels, especially in North America, Europe, and parts of Asia, is contributing to greater awareness and earlier identification of at-risk couples. This, in turn, directly boosts demand for PGD procedures as the logical next step in risk mitigation during IVF cycles. Regions with a high prevalence of consanguineous marriages such as the Middle East, North Africa, and parts of South Asia are witnessing accelerated adoption of PGD due to a higher incidence of autosomal recessive disorders. In these markets, PGD is no longer viewed as a niche option but rather a preventive healthcare tool, supported by both private sector clinics and, increasingly, public health policies. These factors contribute to the growth of this segment.

Product Insights

Based on the category of Product, the Reagents and Consumables segment emerged as the dominating segment in the market for Preimplantation Genetic Testing in 2024. Reagents and consumables including DNA extraction kits, amplification reagents, sequencing buffers, and fluorescent probes are indispensable for each step of the PGT process, from biopsy preparation to genetic analysis. Unlike instruments, which are one-time capital investments, reagents are used for every single embryo tested, resulting in recurring demand and high consumption rates across laboratories and fertility clinics.

The consumable-based model creates a predictable and high-margin revenue stream for diagnostics companies. With each IVF cycle involving multiple embryos and multiple testing stages, labs must continuously procure reagents, making this segment financially central to both small- and large-scale providers. The shift toward next-generation sequencing (NGS), real-time PCR, and microarray platforms in PGT has fueled demand for specialized, high-sensitivity reagents tailored for single-cell or low-input DNA analysis. These advanced reagents are not only more expensive but also enable higher accuracy and faster turnaround times key competitive differentiators in the fertility diagnostics market.

Technology Insights

Based on the category of Technology, the Polymerase Chain Reaction (PCR) segment emerged as the dominating segment in the market for Preimplantation Genetic Testing in 2024. PGT typically involves analyzing a very small number of cells sometimes just one from an embryo. PCR’s high sensitivity and specificity, even with minimal DNA input, make it exceptionally suited for preimplantation diagnostics. It enables accurate amplification of target DNA regions, ensuring reliable detection of inherited genetic mutations or disease-causing variants without compromising embryo viability.

PCR is the gold standard technology for identifying monogenic disorders, such as cystic fibrosis, Tay-Sachs, and sickle cell anemia. Its ability to amplify specific DNA sequences has made it the preferred method in cases where prospective parents are known carriers of hereditary conditions. This targeted capability positions PCR as the go-to technology in high-risk or genetically informed IVF cycles. Compared to more resource-intensive technologies like next-generation sequencing (NGS) or comparative genomic hybridization (CGH), PCR offers a lower cost-per-test and faster turnaround time. These attributes are particularly attractive to IVF clinics and genetic labs in emerging markets or mid-sized operations, where cost-efficiency and speed are key to competitiveness and patient throughput.

Download Free Sample Report

Regional Insights

Europe emerged as the largest market in the global Preimplantation Genetic Testing market in 2024, holding the largest market share in terms of value. European countries maintain well-established regulatory guidelines for the use of assisted reproductive technologies (ART), including PGT. Regulatory bodies such as the European Society of Human Reproduction and Embryology (ESHRE) provide clear protocols and ethical boundaries, facilitating safe and standardized adoption of PGT across clinics. This creates a stable and scalable environment for both service providers and technology vendors.

Many European countries, including Germany, France, Belgium, and the Netherlands, offer partial or full reimbursement for IVF and associated genetic testing procedures, including PGT, under public healthcare systems. This lowers the out-of-pocket burden on patients and drives higher testing volumes, particularly among at-risk couples or those undergoing multiple IVF cycles. Europe is home to some of the most advanced IVF and genetic diagnostics clinics globally, many of which are early adopters of cutting-edge technologies such as NGS-based PGT, digital PCR, and embryo biopsy automation. These capabilities not only attract domestic patients but also fuel the medical tourism segment, particularly in countries like Spain, Czech Republic, and Greece, where treatment costs are lower but clinical standards remain high.

Recent Developments

• In April 2025, The U.S. Food and Drug Administration (FDA) has granted full approval for the combination therapy of nivolumab (Opdivo) and ipilimumab (Yervoy) both developed by Bristol Myers Squibb for use in adult and pediatric patients aged 12 and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC). In addition, the FDA has transitioned nivolumab monotherapy from accelerated to full approval for the same patient group whose disease has progressed after treatment with fluoropyrimidine, oxaliplatin, and irinotecan. This regulatory advancement reinforces the clinical value of immunotherapy in genetically defined subtypes of CRC and expands durable treatment options for patients with limited therapeutic alternatives.
• In September 2023, Natera’s Panorama PGT-M test has achieved a significant regulatory milestone as the first non-invasive prenatal test (NIPT) for single-gene disorders to receive FDA approval. Leveraging a maternal blood sample, the test isolates and analyzes cell-free fetal DNA to screen for a spectrum of inherited genetic conditions. By eliminating the need for invasive procedures such as amniocentesis or chorionic villus sampling (CVS), Panorama offers a safer, earlier, and more accessible option for high-risk pregnancies. This advancement not only enhances patient care but also reinforces Natera’s position as a leader in next-generation reproductive genetics.

Key Market Players

• California Pacific Medical Center (CPMC)
• CombiMatrix Corp
• CooperSurgical, Inc.
• F. Hoffmann-La Roche Ltd.
• Genea Limited
• Genesis Genetics
• Good Start Genetics, Inc.
• IGENOMIX
• Illumina, Inc.
• Invitae Corporation
• Laboratory Corporation of America Holdings

Report Scope:

In this report, the Global Preimplantation Genetic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Preimplantation Genetic Testing Market, By Procedure:

o   Preimplantation Genetic Screening

o   Preimplantation Genetic Diagnosis

• Preimplantation Genetic Testing Market, By Product:

o   Reagents and Consumables

o   Instruments

o   Software

• Preimplantation Genetic Testing Market, By Technology:

o   Next Generation Sequencing (NGS)

o   Polymerase Chain Reaction (PCR)

o   Fluorescent In-Situ Hybridization (FISH)

o   Others

• Preimplantation Genetic Testing Market, By Application:

o   Chromosomal Abnormalities

o   X-linked Diseases

o   Embryo Testing

o   Aneuploidy Screening

o   HLA Typing

o   Other

• Preimplantation Genetic Testing Market, By End User:

o   Fertility Centers

o   Hospitals

o   Diagnostic Centers

o   Research Centers and Academic Labs

• Preimplantation Genetic Testing Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preimplantation Genetic Testing Market.

Available Customizations:

Global Preimplantation Genetic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Preimplantation Genetic Testing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]